{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:37:23Z","timestamp":1784547443241,"version":"3.55.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints and presence of systemic autoantibodies, with a great clinical and molecular heterogeneity. Rheumatoid Factor (RF) and anti-citrullinated protein antibodies (ACPA) are routinely used for the diagnosis of RA. However, additional serological markers are needed to improve the clinical management of this disease, allowing for better patient stratification and the desirable application of precision medicine strategies. In the present study, we investigated those systemic molecular changes that are associated with the RF and ACPA status of RA patients. To achieve this objective, we followed a proteomic biomarker pipeline from the discovery phase to validation. First, we performed an iTRAQ-based quantitative proteomic experiment on serum samples from the RA cohort of the Hospital of Santiago de Compostela (CHUS). In this discovery phase, serum samples from the CHUS cohort were pooled according to their RF\/ACPA status. Shotgun analysis revealed that, in comparison with the double negative group (RF\u2013\/ACPA\u2013), the abundance of 12 proteins was altered in the RF+\/ACPA+ pool, 16 in the RF+\/ACPA\u2013 pool and 10 in the RF-\/ACPA+ pool. Vitamin D binding protein and haptoglobin were the unique proteins increased in all the comparisons. For the verification phase, 80 samples from the same cohort were analyzed individually. To this end, we developed a Multiple Reaction Monitoring (MRM) method that was employed in a comprehensive targeted analysis with the aim of verifying the results obtained in the discovery phase. Thirty-one peptides belonging to 12 proteins associated with RF and\/or ACPA status were quantified by MRM. In a final validation phase, the serum levels of alpha-1-acid glycoprotein 1 (A1AG1), haptoglobin (HPT) and retinol-binding protein 4 (RET4) were measured by immunoassays in the RA cohort of the Hospital of A Coru\u00f1a (HUAC). The increase of two of these putative biomarkers in the double seropositive group was validated in 260 patients from this cohort (<jats:italic>p<\/jats:italic> = 0.009 A1AG1; <jats:italic>p<\/jats:italic> = 0.003 HPT). The increased level of A1AG1 showed association with RF rather than ACPA (<jats:italic>p<\/jats:italic> = 0.023), whereas HPT showed association with ACPA rather than RF (<jats:italic>p<\/jats:italic> = 0.013). Altogether, this study has allowed a further classification of the RA seropositive patients into two novel clusters: RF+A1AG+ and ACPA+HPT+. The determination of A1AG1 and HPT in serum would provide novel information useful for RA patient stratification, which could facilitate the effective implementation of personalized medicine in routine clinical practice.<\/jats:p>","DOI":"10.3389\/fmed.2022.963540","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T20:24:53Z","timestamp":1666988693000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Association of the serological status of rheumatoid arthritis patients with two circulating protein biomarkers: A useful tool for precision medicine strategies"],"prefix":"10.3389","volume":"9","author":[{"given":"Cristina","family":"Ruiz-Romero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Fern\u00e1ndez-Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Illiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Lourido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Quaranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Perez-Pamp\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Calamia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1136\/annrheumdis-2017-212862","article-title":"Defining refractory rheumatoid arthritis","volume":"77","author":"Buch","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.rdc.2017.04.008","article-title":"Precision medicine in rheumatoid arthritis","volume":"43","author":"Bluett","year":"2017","journal-title":"Rheum Dis Clin North Am."},{"key":"B4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2019-216151","article-title":"Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019","volume":"79","author":"Winthrop","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/00002281-199305020-00010","article-title":"Clinical features, diagnosis, and prognosis in rheumatoid arthritis","volume":"5","author":"Morgan","year":"1993","journal-title":"Curr Opin Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1155\/2013\/726598","article-title":"Rheumatoid factors: clinical applications","volume":"35","author":"Ingegnoli","year":"2013","journal-title":"Dis Markers."},{"key":"B7","doi-asserted-by":"publisher","first-page":"797","DOI":"10.7326\/0003-4819-146-11-200706050-00008","article-title":"Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis","volume":"146","author":"Nishimura","year":"2007","journal-title":"Ann Intern Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jbspin.2013.04.004","article-title":"Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: systematic review and meta-analysis of observational studies","volume":"81","author":"Salgado","year":"2014","journal-title":"Joint Bone Spine."},{"key":"B9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S0002-9343(01)00872-5","article-title":"Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies","volume":"111","author":"Lard","year":"2001","journal-title":"Am J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"456","DOI":"10.7326\/0003-4819-152-7-201004060-00010","article-title":"Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis","volume":"152","author":"Whiting","year":"2010","journal-title":"Ann Intern Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B12","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.amjmed.2007.04.005","article-title":"Rheumatoid arthritis: diagnosis and management","volume":"120","author":"Majithia","year":"2007","journal-title":"Am J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cels.2016.02.015","article-title":"Plasma proteome profiling to assess human health and disease","volume":"2","author":"Geyer","year":"2016","journal-title":"Cell Syst"},{"key":"B14","doi-asserted-by":"publisher","first-page":"732","DOI":"10.2174\/1568026611313060006","article-title":"Achievements and challenges of proteomics in the study of rheumatoid arthritis","volume":"13","author":"Ruiz-Romero","year":"2013","journal-title":"Curr Top Med Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/14789450.2017.1321481","article-title":"Defining the proteomic landscape of rheumatoid arthritis: progress and prospective clinical applications","volume":"14","author":"Lourido","year":"2017","journal-title":"Expert Rev Proteomics."},{"key":"B16","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1186\/ar4555","article-title":"Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics","volume":"16","author":"Dennis","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/1744666X.2020.1771183","article-title":"In search of pathobiological endotypes: a systems approach to early rheumatoid arthritis","volume":"16","author":"Tarn","year":"2020","journal-title":"Expert Rev Clin Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1021\/pr200695p","article-title":"Identification of a panel of novel serum osteoarthritis biomarkers","volume":"10","author":"Fern\u00e1ndez-Puente","year":"2011","journal-title":"J Proteome Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/annrheumdis-2020-eular.4450","article-title":"FRI0387 A prognostic model of pre-radiographic knee osteoarthritis: data from the osteoarthritis initiative","volume":"79","author":"Encina","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/978-1-4614-7209-4_8","article-title":"Highly multiplexed antibody suspension bead arrays for plasma protein profiling","volume":"1023","author":"Drobin","year":"2013","journal-title":"Methods Mol Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1136\/annrheumdis-2016-209794","article-title":"Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present","volume":"76","author":"Derksen","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.molonc.2014.03.006","article-title":"Mass spectrometry based biomarker discovery, verification, and validation\u2014quality assurance and control of protein biomarker assays","volume":"8","author":"Parker","year":"2014","journal-title":"Mol Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nbt1235","article-title":"Protein biomarker discovery and validation: the long and uncertain path to clinical utility","volume":"24","author":"Rifai","year":"2006","journal-title":"Nat Biotechnol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.3390\/ijms20184368","article-title":"Proteomics approach for the discovery of rheumatoid arthritis biomarkers using mass spectrometry","volume":"20","author":"Mun","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1002\/elps.200900210","article-title":"The consequences of sample pooling in proteomics: an empirical study","volume":"30","author":"Diz","year":"2009","journal-title":"Electrophoresis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/prca.200780174","article-title":"The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline","volume":"2","author":"Paulovich","year":"2008","journal-title":"Proteomics Clin Appl."},{"key":"B28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/jms.1895","article-title":"Selected reaction monitoring applied to proteomics","volume":"46","author":"Gallien","year":"2011","journal-title":"J Mass Spectrom."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.1038\/s41467-020-19045-9","article-title":"A high-stringency blueprint of the human proteome","volume":"11","author":"Adhikari","year":"2020","journal-title":"Nat Commun."},{"key":"B30","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/s12967-021-03169-7","article-title":"Serum metabolomic and lipidomic profiling identifies diagnostic biomarkers for seropositive and seronegative rheumatoid arthritis patients","volume":"19","author":"Luan","year":"2021","journal-title":"J Transl Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1021\/pr500467d","article-title":"Urinary proteome profile predictive of disease activity in rheumatoid arthritis","volume":"13","author":"Kang","year":"2014","journal-title":"J Proteome Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1038\/emm.2015.120","article-title":"Identification of novel urinary biomarkers for assessing disease activity and prognosis of rheumatoid arthritis","volume":"48","author":"Park","year":"2016","journal-title":"Exp Mol Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e63215","DOI":"10.1371\/journal.pone.0063215","article-title":"Impact of rheumatoid arthritis disease activity test on clinical practice","volume":"8","author":"Peabody","year":"2013","journal-title":"PLoS ONE."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1096\/fj.201802040R","article-title":"Vitamin A decreases the anabolic bone response to mechanical loading by suppressing bone formation","volume":"33","author":"Lionikaite","year":"2019","journal-title":"FASEB J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jbspin.2018.07.002","article-title":"Serum retinol-binding protein 4 is associated with insulin resistance in patients with early and untreated rheumatoid arthritis","volume":"86","author":"Wei","year":"2019","journal-title":"Joint Bone Spine."},{"key":"B36","doi-asserted-by":"publisher","first-page":"7490723","DOI":"10.1155\/2018\/7490723","article-title":"Development of a novel diagnostic biomarker set for rheumatoid arthritis using a proteomics approach","volume":"2018","author":"Mun","year":"2018","journal-title":"Biomed Res Int."},{"key":"B37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13075-020-02405-7","article-title":"Serum biomarker panel for the diagnosis of rheumatoid arthritis","volume":"23","author":"Mun","year":"2021","journal-title":"Arthritis Res Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/nrrheum.2014.192","article-title":"Inflammatory arthritis: Blood coagulation factor drives arthritis pathogenesis","volume":"10","author":"Onuora","year":"2014","journal-title":"Nat Rev Rheumatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement. First of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1056\/NEJM200104123441506","article-title":"Complement. Second of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3389\/fimmu.2018.01057","article-title":"Complement in the initiation and evolution of rheumatoid arthritis","volume":"9","author":"Holers","year":"2018","journal-title":"Front Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.molimm.2019.05.012","article-title":"Complement and its environmental determinants in the progression of human rheumatoid arthritis","volume":"112","author":"Bemis","year":"2019","journal-title":"Mol Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/s41591-022-01880-6","article-title":"The promise of precision medicine in rheumatology","volume":"28","author":"Guthridge","year":"2022","journal-title":"Nat Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.963540\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T20:24:59Z","timestamp":1666988699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.963540\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":43,"alternative-id":["10.3389\/fmed.2022.963540"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.963540","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"article-number":"963540"}}